Robert T. Schooley Dr. Schooley is a Distinguished Professor of Medicine in the Division of Infectious Diseases and Global Public Health at the University of California San Diego. He completed medical school and an internal medicine residency at Johns Hopkins and infectious disease fellowships at the NIH and Massachusetts General Hospital. He joined the faculty of Harvard Medical School in 1981. His research efforts are directed at the pathogenesis and therapy of RNA virus infections. He has been heavily involved in the development of antiviral chemotherapy directed at HIV, HCV and the herpesgroup viruses as well as in research, teaching and infrastructure building efforts in sub-Saharan Africa.
He became Head of the Division of Infectious Diseases at the University of Colorado in 1990. He led the NIH’s AIDS Clinical Trials Group (ACTG) from 1995 until 2002 during which time the ACTG performed many of the seminal studies that defined modern antiretroviral chemotherapy. He then led the ACTG in its expansion from a domestic US research operation into one with a global reach. He was recruited to the University of California San Diego and served as Head of UCSD’s Infectious Diseases Division until 2017. His laboratory is engaged in the discovery of orally bioavailable broadly active antiviral compounds. Following the successful treatment of a faculty colleague at UC San Diego who had a disseminated Acinetobacter baumannii infection with bacteriophages in 2016, he expanded his research interests to include the use of bacteriophages for the treatment of multidrug resistant bacterial infections.
He was awarded a Revelle Medal for distinguished service to the University of California in 2024.